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A comprehensive review of published literature was conducted to elucidate the
genetics, neuropathology, imaging findings, prevalence, clinical course, diagnosis/clinical
evaluation, potential biomarkers, and current and proposed treatments for adult-onset
leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare,
debilitating, and life-threatening neurodegenerative disorder for which disease-modifying
therapies are not currently available. Details on potential efficacy endpoints for future
interventional clinical trials in patients with ALSP and data related to the burden of the
disease on patients and caregivers were also reviewed. The information in this position
paper lays a foundation to establish an effective clinical rationale and address the clinical
gaps for creation of a robust strategy to develop therapeutic agents for ALSP, as well as
design future clinical trials, that have clinically meaningful and convergent endpoints.
Keywords: adult-onset, leukoencephalopathy, leukodystrophy, axonal spheroids, pigmented glia, HDLS, ALSP,
CSF1R

INTRODUCTION
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a rare
neurologic disorder that is characterized by demyelination of white matter of the brain, swollen
axons and pigmented glial cells. The term ALSP encompasses two clinicopathologically similar
entities that were previously known as hereditary diffuse leukoencephalopathy with spheroids
(HDLS) and pigmentary orthochromatic leukodystrophy (POLD) (1). POLD was first described
in 1936 in a family with adult-onset leukodystrophy (2). The term HDLS was first coined in 1984
to describe a Swedish family with adult-onset leukoencephalopathy in which axonal dilatations
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care due to unmet medical needs was derived from MEDLINE
and PUBMED during the above time periods. Review of all
publications was restricted to articles in English or translated
into English. The following primary search terms were utilized
to identify ALSP-related publications:

(spheroids) were a prominent feature (3). However, the original
Swedish family (HDLS-S) was recently found to carry a different
genetic makeup with the affected family members displaying the
alanyl-transfer (t) RNA synthetase (AARS) gene mutation as the
likely cause of Swedish type HDLS with spheroids (4). Thus, this
family belongs to yet another class of genetic disorders identified
as AARS-related leukoencephalopathy (5–7).
Several cases of POLD that fulfill all criteria for HDLS
prior to the discovery of the AARS gene mutation causing
HDLS in the Swedish family, except heritability, have been
described in the literature. These cases are likely sporadic due to
de novo mutations or issues of reduced disease penetrance (8, 9).
Identification of common mutations in the kinase domain of
CSF1R, a gene that regulates mononuclear cell lineages, including
microglia in both HDLS and POLD (1), has provided additional
evidence that HDLS and POLD should be regarded as a single
disease entity (10, 11). In line with this, the diseases are now
summarized as CSF1R-related leukoencephalopathy and for the
purposes of this review are collectively referred to as ALSP.
The genetic, structural and neuropathophysiologic
abnormalities of ALSP result in multiple neurologic symptoms,
such as cognitive dysfunction, movement disorders, motor
impairment, familial dementia and subcortical gliosis of the
Neumann type and neuropsychiatric complications, that result in
diminishing quality of life and eventual premature death (12–17).
At present, some symptoms of ALSP are treated off-label with
existing US Food and Drug Administration (FDA)-approved
drugs that elicit variable levels of short-term efficacy. However,
these symptomatic therapies have limited efficacy and do not
target the etiology or the most debilitating symptoms, such as
rapidly progressive cognitive impairment of ALSP (14). Future
novel therapies that focus on the neuropathophysiologic features
that underlie ALSP are essential to adequately reverse, delay or
stop progression and improve quality of life in patients who are
afflicted with this incapacitating disorder.
This review of the published literature was conducted to
critically evaluate the clinical characteristics of ALSP as a
foundation for rigorous strategy to develop therapeutic agents
targeting ALSP. The review highlights key considerations for
design of human clinical trials for ALSP including clinically
meaningful and convergent endpoints that will lead to the
development of safe and effective therapies for this orphan
neurologic disorder.

• Adult-onset leukodystrophy with neuroaxonal spheroids and
pigmented glia
• Adult-onset leukoencephalopathy with axonal spheroids and
pigmented glia
• ALSP
• CSF1R-related leukoencephalopathy
• Hereditary diffuse leukoencephalopathy with spheroids
• HDLS
• Pigmentary type of orthochromatic leukodystrophy
• POLD.

GENETICS
ALSP is primarily inherited as an autosomal dominant disorder
with CSF1R gene mutations as the most common mutation to
date (14, 18, 19). At least 106 different CSF1R mutations have
been identified in approximately 300 cases published in the peerreviewed literature worldwide (6, 17–32). There is no major
correlation of genotype and phenotypes. Family members with
identical CSF1R gene mutations do not share the same clinical
phenotype (6, 14). However, patients harboring truncating
mutations of CSF1R as well as those that lead to nonsensemediated decay have been shown to have an earlier age of onset
than ALSP patients with substitution mutations (32). Although
de novo mutations of CSF1R have been reported, they are less
common (9, 20). Penetrance of ALSP associated with CSF1R
mutations is high, but incomplete, due to de novo mutations and
genetic mosaicism (6, 9, 13, 33).
The non-mutated CSF1R gene consists of 22 exons. Its normal
gene product is the CSF1R protein, a cell-surface transmembrane
tyrosine kinase receptor with two known ligands for cytokine
colony-stimulating factor 1 (CSF1) and IL-34. Most mutations
of CSF1R that are associated with ALSP are located in the
tyrosine kinase domain (TKD), most frequently in exons 18 and
19 (6). However, novel CSF1R variants in regions such as the
signal peptide, immunoglobulin (Ig) domain, transmembrane
domain, other exons of the TKD, and at the C-terminus, have
been reported (6, 18, 21, 23, 31). Additionally, unique splice site
variants, deletion/insertion mutations and frameshift mutations
have been reported in introns and exons that span nearly all
of CSF1R (6, 17, 19, 21, 23, 24, 26, 31). Figure 1 illustrates
the location of CSF1R mutations in patients with CSF1R-related
leukoencephalopathy. A more detailed presentation of genetic
mutations in CSF1R-related leukoencephalopathy is provided in
Supplementary Table 1.
Survival, development, proliferation, and activation of
mononuclear phagocytic cells and central nervous system
(CNS) microglia are regulated by CSF1R. CSF1R gene
mutations are considered an underlying cause of primary
brain microgliopathies and are linked to CNS damage of ALSP
(20, 34–36).

LITERATURE SEARCH STRATEGY
Published data for the clinical characterization of ALSP were
limited by the small number of patients who are afflicted with
this adult-onset leukoencephalopathy. Observational case studies
comprised the majority of publications for ALSP. The primary
literature search for published and in-press clinical studies of
ALSP were obtained from a MEDLINE search in the timeframe
of January 1, 1980 through October 31, 2020. ALSP literature
subsequent to October 31, 2020 was also monitored through
MEDLINE. Literature relevant to proposed efficacy endpoints,
future interventional clinical trials of ALSP and burden of
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FIGURE 1 | Schematic graph of the CSF1R protein and overview of CSF1R mutations identified in patients with CSF1R-related leukoencephalopathy. CSF1R,
colony-stimulating factor 1 receptor; Ig, immunoglobulin domain. Revised/updated version reprinted with permission from (31).

Biallelic mutations in the AARS gene have been detected in
approximately 20 patients with late-onset leukoencephalopathy
who did not have a CSF1R mutation (37). The AARS2 gene
encodes a mitochondrial enzyme that is essential for loading
alanine onto tRNA during mitochondrial translation (37). Most
of these patients displayed an autosomal recessive inheritance of
AARS2-related leukoencephalopathy with symptoms and brain
neuropathology similar to ALSP (37–40).
Both CSF1R- and AARS2-related leukoencephalopathy share
several neurological symptoms and can present with similar
white matter involvement, predominantly in the frontoparietal
and periventricular regions. However, differences in radiologic
images between patients with CSF1R and AARS2 gene encoding
mutations have been reported in the corpus callosum, in regions
with severe brain atrophy and in patients with AARS2 gene
mutations lacking the unique ALSP-associated calcifications that
are seen on computed tomography (CT) (13, 37, 41). Unlike
CSF1R, the AARS2-related phenotype has not been restricted to
adults, with some cases reported during adolescence (42). The
changes in nomenclature for leukoencephalopathies are a result
of additional understanding of pathology and genetics. The five
main classifications of leukoencephalopathies are CSF1R-related
leukoencephalopathy, AARS2-related leukoencephalopathy,
AARS1-related
leukoencephalopathy,
HDLS-S-related
leukoencephalopathy and CSF1R/AARS1/AARS2-negative ALSP.
The last classification represents cases with a neuropathological
diagnosis of ALSP without mutations in the CSF1R and
AARS2 genes.

Frontiers in Neurology | www.frontiersin.org

Further analyses of brain images and modern neuropathology
are necessary to definitively characterize AARS2-related
leukoencephalopathy. However, due to limited and
conflicting data associated with AARS2, as well as no
known molecular signaling convergence between CSF1R
and AARS2, this clinical review has focused on the term ALSP, a
CSF1R-related leukoencephalopathy.

NEUROPATHOLOGY
Histopathologic evaluation (light and electron microscopy) of
brain tissue from biopsies and autopsies of patients with ALSP
shows multiple morphologic alterations (6, 14, 17, 29, 43–46).
One of the principal neuropathologies consists of vacuolated and
demyelinated white matter that is found primarily within the
corpus callosum, pyramidal tracts and periventricular region of
the frontal and parietal lobes. The degenerate white matter is
often associated with deteriorating neurons and axonal spheroids
that contain neurofilaments, amyloid and ubiquitin. The axonal
pathology is accompanied by macrophages that are engorged
with lipid and myelin. Other characteristic neuropathological
findings of ALSP include deformed astrocytes and pigmented
(iron or lipofuscin) microglia cells that decrease in function and
number with progression of the disorder. Representative lesions
from cases of ALSP are shown in Figure 2.
ALSP is associated with leaky blood brain barrier (BBB)
and cerebrovascular abnormalities similar to cerebral amyloid
angiopathy (CAA) (47). Post-mortem brain sections from ALSP
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FIGURE 2 | Pathologic light microscopic findings from cases with Colony-Stimulating Factor 1 receptor (CSF1R)-related leukoencephalopathy. (A–H) A 78-year-old
man with CSF1R p.M875T. At 71 years of age, he developed cognitive impairment followed by personality and behavior change, depression, executive dysfunction,
apraxia, parkinsonism, and pyramidal weakness. He died after 7 years of disease duration. (A) Luxol fast blue stain shows severe myelinated fiber loss in the superior
frontal and cingulate white matter, whereas the U-fibers are relatively spared. Note the thinning of the corpus callosum (arrow). (B) The axonal spheroids in the affected
white matter are stained with amyloid precursor protein (APP). (C) Numerous axonal spheroids (arrows) are seen within the frontal white matter (hematoxylin and eosin).
(D) 68-immunopositive macrophages in the frontal white matter. (E,F) An axonal spheroid in the white matter depicted by phosphorylated neurofilament (SMI31) (E)
and APP (F). (G) A bizarre astrocyte in the white matter (αB-crystallin). (H) A ballooned neuron in the superior frontal cortex (αB-crystallin). (I,J) A 55-year-old woman
with autopsy-confirmed adult-onset leukodystrophy with neuroaxonal spheroids and pigmented glia, but genetic testing was not performed because DNA was
unavailable. (I) Note the small, calcified lesion (arrow) located in the pericallosal region. An arrowhead indicates the paper-like atrophy of the corpus callosum. (J) An
enlarged image of the calcification. Bars in A, B, and I = 5 mm; C and D = 100 µm; E, F, G, and H = 50 µm; and J = 400 µm. Reprinted with permission from (6).

patients were stained for Claudin-5, a key mediator of tight
junction function at the BBB in areas of dense amyloidbeta integrity and demonstrated a non-linear distribution
of Celaudin-5 in tandem with extravasation of IgG and
fibrinogen. These findings implicate BBB disruption. Perivascular
localization of CD68- and CD163-positive cells in the brain of
ALSP patients suggest that peripheral macrophages are recruited
to the vasculature (47). Identification of donor chimerism in the
CSF (cerebrospinal fluid) obtained from patients who underwent
hematopoietic stem cell transplantation (HSCT) further supports
this observation (48).

Frontiers in Neurology | www.frontiersin.org

Additionally, the proinflammatory cytokine, granulocyte
macrophage colony stimulating factor (GM-CSF), was
shown to be significantly upregulated in the gray matter
on post-mortem analysis of brain tissue from patients
with ALSP and migration and adhesion-related molecules
derived peripheral blood monocytes were also significantly
upregulated, suggesting widespread immune dysfunction
(28, 32). More robust characterization of the innate and
adaptive immune system throughout the course of disease
progression is warranted to understand its potential role in
ALSP pathobiology.
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IMAGING

with slight atrophy of cerebral white matter and slight dilation
of the lateral ventricles. Stage III presents wide-spread axon loss
in cerebral white matter and dilation of the lateral and third
ventricles without prominent axon loss in the brainstem and
cerebellum. Stage IV is characterized by extensive damage of
cerebral white matter with pronounced dilation of the ventricles
and loss of axons in the brainstem and/or cerebellum. With
MRI, patients with ALSP have been shown to exhibit bilateral
asymmetric white matter lesions that were patchy (as described
in histopathology of Stage I), particularly within frontal and
parietal lobes in early stages of the disorder. These lesions
become confluent and expand into temporal and occipital lobes
in later stages of the disease (6, 13, 22, 50, 51), as shown
in histopathology of ALSP during Stages III, IV. Based on
clinical manifestations of the disease, a frontal lobe syndrome
is typical in the early course of the disease and aligns with the
histopathology and imaging findings. The thinning of corpus
callosum is evident from histopathology of ALSP Stage I and
is also evident in the early phases of the disease with MRI.
Similarly, both histopathology and MRI indicate that ventricular
dilation begins in relatively earlier stages of the disease with
consistent progression. Consistent with histopathology, brain
atrophy starts in the cerebrum and can affect other brain regions
over time (22). Other common findings of histopathology and
MRI includes thinning of cerebral cortex or cortical atrophy
as well as degeneration of projection fibers (e.g., corticospinal
tracts, internal capsule, pyramidal tracts). Notably, some features
such as involvement of deep gray matter are rarely seen on MRI
and are only present in histopathology of Stage IV. Contrastenhanced MRI studies in genetically diagnosed ALSP have also
revealed a breakdown of the BBB integrity as indicated by
the perilesional accumulation of the contrast agent gadobenatedisodium (Gd-BOPTA) (47).
CT images have identified characteristic stepping-stone
calcification of periventricular white matter near the frontal
horns in up to 50% of patients with ALSP (6, 13) (Figure 4). Brain
calcifications have been detected in patients with asymptomatic
ALSP and the CSF1R mutation (13, 55). The relationship
between formation of calcifications and the underlying disease
mechanisms are unclear.
To date, alternate and advanced imaging techniques have been
tested or proposed for use in ALSP and other leukodystrophies.
For example, DTI, which quantifies the white matter integrity
through analysis of water diffusivity, is a unique analysis
technique applied to Diffusion Weighted Imaging (DWI)
scans to characterize global diffusivity but also along specific
directionality. A DTI study (56) was conducted in patients with
leukodystrophy across different age groups and showed that DTI
could be used to quantitatively capture changes in the white
matter integrity in terms of magnitude and directionality and
correlate the diffusivity abnormalities with ALSP progression,
both spatially and temporally.
Magnetic resonance spectroscopy reveals markedly increased
levels of cholin, myo-inositol and lactate and a decreased Nacetylaspartate peak in ALSP. These findings are clearly different
from cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy (CADASIL) (51).

Magnetic resonance imaging (MRI) of patients with ALSP
typically demonstrates abnormal white matter signal with
hyperintense (T2) and fluid-attenuated inversion recovery
(FLAIR) lesions and diffusion tensor imaging (DTI) identifies
diffusion restriction lesions (6, 13, 49–52). Figure 3 presents the
typical abnormal brain MRI findings in patients with ALSP.
White matter lesions are some of the most common
neuroradiological findings on MRI in ALSP. They can be
symmetric or asymmetric, patchy or confluent and tend to
involve different lobes of the brain during the evolution of the
disease. A study of 122 patients with ALSP and CSF1R mutations
reported the presence of bilateral white matter lesions in 96%
of the patients (13). Similarly, a subsequent MRI study found
bilateral, predominantly frontal and parietal, T2/FLAIR white
matter hyperintensities associated with T1 hypointensities in 16
patients with ALSP (22). This study also reported progression
of white matter lesions on imaging in a subset of 13 patients
with follow-up MRIs. White matter lesions were identified with
either a patchy or confluent appearance and the occipital and
temporal lobes showed white matter lesion involvement in later
stages of the disease (51). A summary review of white matter
lesions confirmed that they are often asymmetric, patchy, and
focal especially in the early stages of the disease, but with time
they become confluent (50). Lesions are found predominantly
in frontoparietal and periventricular areas. Overall, previously
published MRI data identify some distinctive features of white
matter lesions in patients with ALSP. These data are included
in the diagnostic criteria (53) that may prove useful in assessing
disease progression.
Focal and global brain atrophy as well as thinning of cortex
and corpus callosum are other hallmarks found in ALSP. Brain
atrophy was shown in 94% of cases (15/16), predominant in
the frontal (40%, 6/15) or frontoparietal (53%, 8/15) areas,
and progressed in association with larger white matter lesions
over time (22). Dilation of the lateral ventricles was identified
in a population of 122 subjects (13). Thinning of the corpus
callosum was evident in 88% (23/26) and cortical atrophy in
92% (24/26) of patients (13). Similarly, a case study revealed
corpus callosum abnormalities were present in 81% (13/16)
and atrophy in 88% (14/16) (22). A striking finding in ALSP
in some patients is areas of diffusion restriction that can be
confused with stroke (often leading to misdiagnosis), but do
not occur in vascular distributions. In summary, MRI data
across several studies consistently demonstrates brain volumetric
changes including cortical and corpus callosum thinning in
ALSP patients highlighting the importance of utilizing advanced
analysis techniques for systematic investigation of regional brain
volume and cortical thinning as imaging markers for progression
of ALSP.
Overall, MRI, as a non-invasive approach, has consistently
shown a variety of features of ALSP that demonstrate a strong
radiological, pathological and clinical correlation. Four stages of
ALSP have been described on the basis of degree of axon loss
(54). Stage I is depicted as patchy axon decline in cerebral white
matter without atrophy. Stage II reveals large patchy axon loss
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FIGURE 3 | Brain magnetic resonance imaging (MRI)/computed tomography (CT) findings from cases of Colony-Stimulating Factor-1 Receptor (CSF1R)-related
leukoencephalopathy. (A–D,F,H) A 44-year-old woman with CSF1R p.G589R. (E) A 27-year-old woman with CSF1R c.2442 + 5 G > A. (G) A 31-year-old woman
with CSF1R p.A652P. (A,B), Bilateral diffuse white matter hyperintensity with pyramidal tract involvement (arrows in A), cortical atrophy, and enlarged lateral ventricles
on fluid-attenuated inversion recovery MRI. (C) Longitudinal pyramidal tract involvement (arrows) on coronal T2-weighted image. (D) Thinning of the corpus callosum
with hyperintensity on sagittal fluid-attenuated inversion recovery image. (E) Hyperintensity lesions in the subcortical white matter on diffusion-weighted image. (F)
Small calcifications located bilaterally near the anterior horns of the lateral ventricles on brain CT image. (G) Calcifications in parietal subcortical white matter. (H)
Stepping-stone appearance of calcifications (arrows) in the frontal pericallosal region on sagittal CT image. Reprinted with permission from (6).

ALSP was extremely limited until the discovery of CSF1R-related
gene mutations. Although still rare, genetically diagnosed CSF1Rrelated ALSP has been increasingly recognized around the world
(identified in Canada, China, Croatia, Germany, Italy, Japan,
Netherlands, Norway, Poland, Saudi Arabia, Sweden, South
Korea, Taiwan, United Kingdom, and United States) since 2012.
Therefore, this disease obviously has global distribution and
many patients may still be underdiagnosed (6).
In a series of leukodystrophy cases, 12 probands or cases
with mutations in the CSF1R gene were identified (58). These
mutations were responsible for 11% (12 of 114) of the overall
series, including 7% (6 of 88) of the clinical series of patients with
leukodystrophy on brain MRI and 20% (5 of 25) of the patients
with a histopathological diagnosis of HDLS. In a smaller series
in which 25 patients with adult-onset leukoencephalopathy of
unknown cause were screened for mutations in the CSF1R gene,
six patients (24%) showed a CSF1R mutation (9).
One study estimated the frequency of CSF1R-related
leukoencephalopathy at 10% (5 of 48) of adult-onset
leukoencephalopathies and suggested that it could be the
most common type (5). Approximately one-third of patients
with genetically proven CSF1R-related ALSP have been reported
in the adult-onset leukoencephalopathy population in Japan
(13). Based on an increasing number of such case report studies,
patients with CSF1R-related ALSP constitute an overall global
incidence range of 10-25% of the adult-onset leukodystrophy
population (14).
As of 20 May 2021, based upon the available peer-reviewed
literature, the total estimated global prevalence of mendelian

Single photon emission computed tomography (SPECT) in
combination with DaTscanTM I-123 ioflupane injection and
positron emission computed tomography (PET) have been
used for brain imaging of neurodegenerative disorders such
as ALSP, Alzheimer’s Disease (AD) and Parkinson’s Disease
(PD). These imaging techniques provide valuable information
on clinical diagnosis, pathology, disease progression and patient
care (57). For example, SPECT with DaTscanTM reveals loss
of presynaptic dopamine transporter function in the striatum
and 18 F-[fluorodeoxyglucose] PET illustrates diffuse cortical
hypometabolism primarily in fronto-parietal areas of patients
with ALSP (1, 6, 58). Finally, optical coherence tomographic
imaging has also shown atrophy of the retinal nerve consistent
with optic tract degeneration in a single case of ALSP (59).

PREVALENCE
Mendelian adult-onset leukodystrophies are a spectrum of rare,
chronic, complex and progressive neurologic disorders that affect
the white matter of the CNS, with a total estimated global
prevalence of 300 cases per million (60). However, dedicated
epidemiological studies are missing to support the available
prevalence data. The worldwide incidence of these disorders has
more recently been reported to be 5 per 100,000 (61). Future
studies are critical to fully evaluate the epidemiology of adultonset leukodystrophies.
Historically, the diagnosis of ALSP was previously dependent
on histopathologic findings from brain biopsies or autopsies.
The number of patients who were definitively diagnosed with
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disorders in the absence of genetic confirmation of CSF1R gene
mutations. The presenting cognitive, neuropsychiatric and motor
symptoms and the rate of progression of symptoms varies among
patients and within family members who carry the same CSF1R
mutation (14). A frontal lobe syndrome, which is characterized
by cognitive impairment, neuropsychiatric changes (depression,
minimal social inhibition and poor insight) and limited motor
dysfunction, is usually detected during the early stages of ALSP,
and some patients may exhibit mild seizures (14, 53, 63).
The type and incidence of initial core clinical symptoms of
ALSP were rigorously evaluated in a case series and literature
review of 106 out of 122 male and female patients diagnosed
with ALSP (13). Cognitive impairment (59%), neuropsychiatric
symptoms (44%) including anxiety, depression, apathy,
indifference, abulia, irritability, disinhibition and distraction,
motor dysfunction (38%) involving parkinsonian symptoms,
gait disturbances and spasticity, speech difficulty (19%) and
other symptoms (8%) including stroke-like episodes, sensory
dysfunction, dizziness, fatigue and epilepsy, were reported in
the early stages of ALSP. Approximately half of the 106 cases
presented with 2 or more symptoms during early onset of ALSP.
The rate of motor dysfunction was higher than the rate of
cognitive impairment in women aged 20-29 years.
Progression of the neuropsychiatric aspects of ALSP can lead
to further cognitive decline, severe depression, apathy, anxiety,
irritability and familial dementia and subcortical gliosis of the
Neumann type. Progressive motor symptoms are numerous
and often include parkinsonian signs, such as tremor, rigidity,
bradykinesia and postural instability. Additional progressive
symptoms involve higher cortical functions (aphasia, agraphia,
acalculia and very frequently apraxia), pyramidal detriments
(hyperreflexia, hypertonia, spasticity and bilateral Babinski
signs), bulbar signs (dysarthria, dysphagia and slurred speech),
cerebellar abnormalities (ataxia, dysmetria, intention tremor
and gait disturbances), and seizures. Development of sensory
symptoms involve a diminished sense of vibration, position,
touch and pain perception (6, 13, 14).
Rare progressive events of ALSP may include stroke-like
episodes, bone cysts and optic and peripheral nerve dysfunction
(6, 13, 14). Progression of the cognitive and motor deficits elicits
a significant diminution in quality of life and disruption of
employment. In the final stages of the disorder, loss of speech
and voluntary movements, confinement to bed and a vegetative
state are evident. Infections such as pneumonia often result in
death (14).

FIGURE 4 | TREM2 signaling cascade and convergence with CSF1R
signaling. Schematic representation of TREM2/DAP12 signaling in microglia.
Ligands and downstream signaling of TREM2/DAP12. Of the known TREM2
ligands, only ligands that highly correlate with neural diseases are shown.
Upon ligand binding to TREM2, two tyrosine residues within the ITAM motif of
DAP12 are phosphorylated, which recruits Syk kinase to activate downstream
signaling molecules, such as ERK, PI3K, PLCγ, and Vav. Src, the main effector
of CSF1R, is a kinase supposed to phosphorylate the ITAM tyrosine residues.
Reprinted with permission form (94).

adult-onset leukodystrophies is 300 cases/million and 10-25%
of those cases are projected to be CSF1R-related ALSP patients.
In the United States population, the estimated prevalence of
CSF1R-related ALSP patients is 9,970-24,926 (60). Additional
epidemiological studies are warranted to fully characterize the
prevalence of ALSP.

CLINICAL COURSE
The mean age for onset of symptoms of ALSP is primarily
in the 4th decade but can span from early adulthood to the
8th decade (14). The cumulative incidence of CSF1R-associated
ALSP increases from 10% at 27 years of age, to 50% at 43 years
of age and to 95% at 60 years of age, for a median age of 43 years
(13). One of the few large case studies and literature reviews (122
patients) reported that the onset of ALSP symptoms occurs on
average earlier in women (40 years) than in men (47 years) (13).
Progression of the disorder from onset of symptoms to death
varies from 2 to >30 years (mean, 6-8 years) (13, 62).
ALSP is clinically delineated by cognitive dysfunction with
neuropsychiatric and motor symptoms. Signs and symptoms
tend to be non-specific in the early stages of the disorder
and may be difficult to distinguish from other neurological
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DIAGNOSIS AND CLINICAL EVALUATION
The diagnosis of ALSP requires exclusion of autosomal dominant
disorders with symptoms that overlap with ALSP, including
Alexander disease (bulbar/pseudo bulbar signs, ataxia and
spasticity), adult-onset autosomal dominant leukodystrophy
(ADLD) (impaired cognition, pyramidal and cerebellar signs),
cerebral autosomal dominant arteriopathy (subcortical infarcts
and leukoencephalopathy, frontal lobe syndrome and white
matter lesions), frontotemporal dementia (FTD) (frontal lobe
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mutation and 28 cases (88%) that had a diagnosis of CADASIL.
Moderate specificity for accurate diagnosis of CSF1R-related
leukoencephalopathy relative to mutation-negative cases and the
high specificity of CSF1R-related leukoencephalopathy relative
to CADASIL cases were confirmed by this MRI diagnostic
platform (53).
A more recent case study of 135 patients who were suspected
of having adult-onset leukoencephalopathy due to CSF1R
mutation was conducted to further evaluate the sensitivity and
selectivity of diagnostic factors (30). As a result of genetic
testing, 28 cases were positive for a CSF1R mutation and
107 cases were negative for a CSF1R mutation. Younger age
at onset, Parkinsonian symptoms, reduction in the corpus
callosum volume and presence of diffusion- restricted lesions
were important predictors of CSF1R-positive cases whereas
involuntary movements and brain stem or cerebellar atrophy
were poor predictors of CSF1R-positive cases. The model
confirmed high sensitivity for probable or possible CSF1R-related
leukoencephalopathy at 81%, but like many models, suffered
from lack of specificity at 14%.
Due to the above studies, the diagnostic accuracy for
CSF1R-related leukoencephalopathy has significantly improved
in recent years. After diagnosis of ALSP, clinical evaluations by
a neurologist, psychiatrist, orthopedist, physical therapist and
occupational therapist are periodically conducted for surveillance
and for the treatment of symptoms with progression of the
disorder. These assessments involve neurologic examination with
cognitive and psychiatric evaluations, MRI of the brain for white
matter lesions, brain atrophy and thinned corpus callosum and
electroencephalograms (EEGs) for suspected seizures. Lumbar
punctures have been proposed for the assessment of protein
and cellular content. While not yet measured routinely for
clinical management, serum NfL is an easily accessible, putative
biomarker for following native disease course in ALSP (67) and
potential treatment response.

pathology and pyramidal/extrapyramidal signs) and early-onset
AD (executive dysfunction, personality derangement and similar
onset of age) (14). Several other disorders such as autosomal
recessive or X-linked leukodystrophies (vanishing white matter
disease, metachromatic leukodystrophy, Krabbe’s disease or Xlinked adrenoleukodystrophy) as well as mitochondrial diseases
(e.g., Leigh syndrome) have overlapping clinical symptoms with
ALSP (14) and further complicate the differential diagnosis
of ALSP, confirming the need for genetic testing, such as a
leukodystrophy panel or whole exome testing (no family history)
or gene testing (known family history).
Diagnosis of suspected ALSP is a multistep process (14, 30, 53,
64) that is typically initiated in patients, with a positive family
history, who exhibit one or more of a variety of characteristic
symptoms, such as personality changes, impaired cognition,
memory derangement, bouts of depression or motor dysfunction,
such as muscle weakness, impaired gait, slow movement, rigidity
and tremor. MRI scans show distinctive radiological signs that
are used to identify white matter lesions in the frontal region,
corpus callosum and corticospinal tracts of the brain, as well as
recognize enlarged ventricles due to cerebral atrophy.
A three-step MRI differential diagnostic approach has been
proposed for several adult leukodystrophies, including ALSP.
The first step involves identification of symmetric white
matter. The second step consists of classification of the white
matter into one or more of six patterns (parietal-occipital,
frontal, periventricular, subcortical, brainstem involvement, and
cerebellar involvement). The third step entails evaluation of
five distinct characteristics (enhancement, lesions with signal
intensity similar to CSF, susceptibility-weighted MRI signal
intensity abnormalities, atypical peaks of MRI spectroscopy and
spinal cord involvement) (65).
Medical history of family members can inform if
ALSP is present in the lineage. The diagnosis of ALSP
is verified through genetic testing and identification of a
mutated CSF1R gene in most patients who are afflicted with
ALSP (13, 14, 22, 30, 31, 53, 66).
Diagnostic criteria for CSFIR-related ALSP without a genetic
test diagnosis have been developed and validated through a
retrospective case study (Supplementary Table 2) (53), although
a genetic test is recommended and finding of a known pathogenic
CSF1R mutation supercedes these criteria. “Probable” and
“possible” diagnostic designations were the outcomes based
upon retrospectively specified clinical characteristics of ALSP,
including age at onset ≤ 60 years, >2 impairments (e.g.,
cognitive, pyramidal, Parkinsonism or epilepsy), autosomal
dominant inheritance and brain MRI/CT findings, such as
bilateral cerebral white matter lesions and thinning of corpus
callosum. Among the 83 patients that were positive for a CSF1R
mutation, 50 (60%) had a “probable” diagnosis and 32 (39%)
had a “possible” diagnosis of ALSP, resulting in a high level
of sensitivity.
The specificity of an MRI diagnosis for CSF1R-related
leukoencephalopathy was determined by retrospective evaluation
of 53 cases of CSF1R-mutation-negative leukoencephalopathy
and 32 cases of CADASIL. The MRI diagnostic algorithm
excluded 22 cases (42%) that were negative for a CSF1R
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CURRENT TREATMENT FOR
MANAGEMENT OF SYMPTOMS
Currently, there are no regulatory-approved, disease modifying
therapies for ALSP. Symptomatic treatments target the
temporary relief of motor, mood and behavior symptoms
and provide supportive care with the goal of maintaining
quality of life as the disorder progresses (6). Although several
regulatory-approved pharmacotherapies are prescribed off-label
to treat the symptoms of ALSP, such as spasticity or seizures,
that are comparable to those of other neurologic disorders (14),
none of these pharmacotherapies target the cause or slow the
progression of ALSP.
Dopaminergic drugs are used off-label to treat Parkinsonian
symptoms with limited effectiveness because dopaminergic
neurons are usually unaffected in the substantia nigra of patients
with ALSP (68). As some symptoms of ALSP are similar to
those of patients with AD, cholinesterase inhibitors have been
prescribed but elicit minimal stabilization of symptoms of
cognitive deficiency in patients with ALSP (69).
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and Charcot-Marie-Tooth disease (73–85). A recent case
control study demonstrated that serum and CSF levels of NfL
protein were markedly higher in patients with symptomatic or
presymptomatic (i.e., carriers) CSF1R-mutation-positive ALSP
vs. that in healthy control subjects or in patients with MS (67).
NfL protein levels in CSF were over 30-fold higher in patients
with CSF1R-mutation-positive ALSP than in age-matched
control subjects and serum NfL protein levels were significantly
higher in symptomatic patients compared to presymptomatic
CSF1R mutation carriers. Comparatively, patients with AD,
ALS, FTD, LBD, and PSP have been shown to have CSF NfL
levels approximately 2.3-fold, 7.2-fold, 3-fold, 2.8-fold, and 3.5fold higher than healthy controls, respectively (82). Based on
compelling evidence from case studies of ALSP and other
neurodegenerative disorders, levels of NfL protein in serum
and CSF may be predictive of clinical efficacy and should be
rigorously tested as a potential biomarker and surrogate clinical
endpoint for future clinical trials of therapeutic agents for ALSP.
Tau proteins regulate stability of microtubules in axons and
neurons of the CNS. Abnormal levels of total tau protein
concentrations (tauopathies) in CSF have been identified as a
potential therapeutic biomarker in several neurodegenerative
disorders, including AD, PD, progressive supranuclear palsy
and ALSP (14, 86–88). Glial fibrillary acidic protein reinforces
the cytoskeleton of astrocytes and increased expression often
correlates with various types of neurodegenerative pathology.
Increased concentrations of this protein have been observed in
patients with ALSP and in patients with brain injuries (14, 89).
Tau and glial fibrillary acidic proteins should also undergo further
evaluation as potential biomarkers and surrogate endpoints for
clinical trials of therapeutic agents for ALSP.

Antidepressants offer modest short-term efficacy for
depression (14) and antipsychotic drugs are occasionally
prescribed with caution for patients with ALSP because of
the side effects including extrapyramidal symptoms and
safety issues. There is risk of suicidal ideation associated
with these agents but they may be useful in highly aggressive
patients (14). Muscle relaxants for spasticity, anti-epileptic
medications (e.g., benzodiazepines, gabapentin, valproic acid)
generalized epileptic seizures and antibiotics for pneumonia
and urinary tract infections have shown some benefit in
patients with ALSP (6). Patients with ALSP generally fail to
respond to immunomodulators, such as steroids, interferon
and cyclophosphamide (6). The efficacy of other approaches,
such as allogeneic HSCT (27, 48, 70, 71) and pre-symptomatic
immunosuppression (72) have shown potential effectiveness in
small retrospective case reports but have not yet been tested in
controlled clinical trials.
Food consumption patterns and nutrition should be
monitored throughout the disease course, as symptoms of
ALSP can include dysphagia and gastrointestinal dysfunction,
such as constipation and fecal incontinence. Urinary or urge
incontinence may be alleviated by medication, scheduled
toileting and intermittent or permanent catheterization of the
urinary bladder. Physical, occupational and speech therapy are
essential to maintain patient mobility, self-dependence and
execution of daily living for as long as possible. Professional
counseling is important to educate the patient and relatives
on the symptoms and progression of ALSP and ensure a
supportive family structure. However, due to the rareness of the
disease, only a small number of experts in ALSP are available.
Genetic counseling of the patient and relatives is necessary to
explain the probability of inheritance and assist in the decision
making of genetic testing of relatives (6, 14, 44). Referral to
leukodystrophy communities/relevant foundations (e.g., Sisters’
Hope Foundation) is essential for ongoing patient, family and
caregiver support.

CURRENT AND PROPOSED
INTERVENTIONAL CLINICAL STUDIES OF
THERAPEUTICS
Information on the use of HSCT for the treatment of ALSP
is derived from four case studies with a limited number of
patients (n=11) and inadequate controls. In the earliest case
study, 1 of 4 siblings with ALSP underwent an allogeneic
HSCT and experienced stabilization of ALSP symptoms and
personality within 6 months, together with no progression in
motor symptoms over the next 15 years (70). However, as
the authors point out, the stabilization of symptoms in this
transplanted patient may have developed spontaneously and
therefore was potentially unrelated to HSCT. In a second case
study of a single ALSP patient (71), the patient displayed
deterioration with pyramidal symptoms and was confined to
a wheelchair after 3 months of HSCT. Complications during
HSCT involved hemorrhagic cystitis and pyelonephritis but
both resolved after 6 months. Some stabilization of neurologic
symptoms began at 6 months after allogeneic HSCT. Modest
improvement in symptoms of ALSP occurred during the 30month post-transplant period, including minimal limb mobility
and stabilized cognition and mood on the Expanded Disability
Status Scale (EDSS), concomitant with a decrease in lesions

POTENTIAL NEUROPATHOPHYSIOLOGIC
BIOMARKERS
A limited number of clinical case studies have been performed
to evaluate the neuropathophysiologic biomarkers of ALSP.
Abnormal levels of cytoskeletal proteins, such as NfL protein,
tau protein, and glial fibrillary acid, were originally identified as
potential biomarkers in 4 cases of ALSP (33, 62). In a more recent
small study of 4 patients with CSF1R-mutation-positive ALSP,
profiling of peripheral blood mononuclear cells (PBMCs) showed
a basal proinflammatory phenotype (28).
NfL proteins support the cytoskeleton of neurons and
myelinated axons, and elevated levels of NfL in CSF and
blood are believed to be indicative of neuron death and
axonal deterioration in a growing number of neurodegenerative
disorders, including AD, PD, FTD, Lewy body dementia (LBD),
progressive supranuclear palsy (PSP), Down syndrome, multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS), Huntington’s
disease, X-linked adrenoleukodystrophy, spinocerebellar ataxia
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Replacement of microglia by proliferation of resident microglia,
infiltration of microglia-like cells and HSCT (described above)
have been evaluated as therapeutic approaches for CSF1R-related
leukoencephalopathy in mouse models and shown preliminary
evidence of efficacy (91). Future human case studies and clinical
trials of these microglial replacement therapies will assess the
efficacy and safety in patients with ALSP.
The response of microglial cells to changes in the environment
of the CNS is activated through a triggering receptor on
myeloid cells 2 (TREM2) and its associated protein kinase
complex, kDa transmembrane protein (DAP12) (94). The
TREM2/DAP12 complex initiates a signaling cascade, including
phosphorylation of the spleen tyrosine kinase (SYK). This
phosphorylation subsequently activates multiple intracellular
pathways of microglia controlled by TREM2 signaling cascades,
including phosphatidylinositol 3-kinase, protein kinase C,
extracellular regulated kinase, Akt serine/threonine kinase and
the elevation of intracellular calcium (95, 96). TREM2-mediated
activation pathways include phagocytosis, cell survival and
proliferation, modulation of inflammation and regulation of
lipid metabolism (97, 98) potentially enabling neuroprotection
and nerve tissue regeneration. Mutations in TREM2/DAP12
are associated with the autosomal recessive disorder NasuHakola disease, which is characterized by bone cysts, muscle
wasting, and demyelination phenotypes (58). Animal and
human genetic studies have demonstrated that microglia
without TREM2 or with mutated TREM2 do not convert
to an activated stage and subsequently lead to development
and/or progression of neurologic disorders. Furthermore,
animal models of PD, AD, ALS and demyelinating disease
display dysregulation of TREM2/DAP12 signals that promotes
pathogenesis of neurodegeneration (94). Based on extensive
biochemical research, CSF1R and TREM2 share significant
portions of their signaling function that converge via DAP12
and SYK phosphorylation. ALSP is presumably caused by
haploinsufficiency of CSF1R due to inactivating mutations,
usually in the kinase domain, which results in dysfunctional
microglia leading to neurodegenerative pathology, such as
neuroinflammation, dementia, and white matter loss (29).
Therefore, the signaling pathway convergence between TREM2
and CSF1R, shown in Figure 4, provides the possibility for
TREM2 activation to rescue or compensate for CSF1R loss of
function (94).
It is apparent that there is dearth of therapies that
directly target the etiology of ALSP. Clinical studies should be
conducted to develop safe and effective therapies that address
the etiology of ALSP, a rare, debilitating and life-threatening
neurologic disorder.

in the white matter through diffusion weighted imaging and
reduced FLAIR hyperintensities on MRI. In a third case study
of 2 patients with ALSP (27), some stabilization of cognitive
deficits, functional status and gait impairment occurred over
2 years after transplant despite some continued neurological
deterioration. There was no evidence of graft vs. host disease
(GVHD), but a major infection developed in one patient and
seizures were evident in the other patient. MRI scans of the
brain demonstrated stabilization of FLAIR-related lesions in the
white matter at 1 year, with continued stabilization over 2 years
post-transplant. In a fourth case study, seven ALSP patients
received HSCT at different stages of the disease (48) to determine
the effect on progression. Six of the seven patients had several
clinical evaluations at various time points post-transplant (one
patient died post-transplant) and trended toward stabilization on
motor examinations, cognitive scores and/or MIR abnormalities.
Other minor clinical improvements tended to be empirical and
subject to investigator bias because a negative control group
was not included. Three patients developed GVHD. Overall, the
four published case studies of HSCT with limited numbers of
patients (n = 11) showed minimal to modest stabilization or
improvement of ALSP symptoms with significant safety concerns
including death of one patient.
Although the data on HSCT in ALSP are limited, given
the challenges and risks of HSCT for the treatment of
leukodystrophies and associated complications, clinical
guidelines have been developed for pediatric patients with
leukodystrophies and are likely applicable to adult patients as
well (90). These guidelines focus on the assessment depending
on the type of HSCT, patient eligibility, donor selection,
conditioning regimen, pre-transplantation, supportive care
and posttransplant follow-up. Early detection and therapy
of leukodystrophies are highly recommended along with a
close working relationship between families of patients and
healthcare providers.
Microglial replacement, which represents a potential therapy
for CSF1R-related leukoencephalopathy, has been the focal
point of intense non-clinical research and may enter into
clinical studies in the near future (91). Microglia are resident,
innate immunity cells of CNS that monitor and maintain the
robust physiology of the CNS. Microglia respond to various
types of cellular and metabolic distress signals in the CNS
and regulate responses for repair and remyelination of nerve
fibers, phagocytosis of dead cells, maintenance of synapses
and blood vessels and control of neuroinflammation associated
with infection and carcinoma. The CSF1R cell-surface receptor
is expressed predominantly on microglia in the brain (92)
and in the spleen, placenta and appendix according to the
Human Protein Atlas. Mutations of the CSF1R gene codes are
transcribed to mutant CSF1R protein with suboptimal receptor
function that leads to dysfunctional monocytic lineage cells with
reduced survival and abnormal distribution (93). Thus, impaired
microglia are recognized as a primary causative factor underlying
CSF1R-related leukoencephalopathy.
The strong link between CSF1R mutations and pathologic
microglia has resulted in further classification of CSF1R-related
leukoencephalopathy as a CNS primary microgliopathy (91).
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POTENTIAL EFFICACY ENDPOINTS FOR
FUTURE INTERVENTIONAL TRIALS
Due to the relatively recent identification of the CSF1R gene
mutations, specific clinical trial methodologies for ALSP are still
evolving. Meaningful biomarkers and efficacy endpoints that
capture disease progression will be essential for interventional
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ability to inhibit cognitive interference that takes place when
the processing of an initial stimulus affects the simultaneous
processing of a second stimulus (112). Due to the reduced
capacity of ALSP patients to focus on tasks for a prolonged period
of time along with loss of speech and dysfunctional arms and
hands, it will be critical to select a battery of cognitive tests that
have the flexibility to conduct simple and time expedient verbal
or written versions.
Additional clinical scales of cognitive dysfunction that
have the potential to yield endpoints for clinical trials of
ALSP are the well-known CERAD test battery for AD, Saint
Louis University Mental Status (SLUMS) (113), the Memory
Impairment Screen (MIS) (114, 115), Clock Drawing Test
(CDT) (116), Clinical Dementia Rating (CDR) scale (117), CDR
plus National Alzheimer’s Coordinating Center Frontotemporal
Lobar Degeneration (FTLD) rating (118) and Neuropsychiatry
Unit Cognitive Assessment Tool (NUCOG) (119). These scales
(described in Supplementary Table 3) are semi-quantitative and
have acceptable levels of sensitivity and specificity. Further
evaluation of these scales will determine their degree of
applicability as endpoints for therapeutic clinical trials of ALSP.

clinical trials of ALSP. Based upon case studies of ALSP,
neuroimaging markers (MRI and CT) and clinician- and patientrated scales for cognitive, psychiatric and motor dysfunction,
coupled with global impression of change assessments, quality
of life and disability evaluations, will likely yield convergent
endpoints to evaluate efficacy and justify clinical meaningfulness
of novel therapeutic agents. Given the similarity of some signs
and symptoms of ALSP with FTD, PD and MS, some of the
clinical trial methodologies for efficacy endpoints of the related
neurologic disorders may be applicable to clinical trials of ALSP.

Cognitive Decline
Cognitive decline is a clinically significant symptom of ALSP that
presents early in the disorder and progresses rapidly (6, 14). In
view of this finding, identification of cognitive assessments that
capture deficits and decline is an important predictive clinical
endpoint for interventional clinical trials of ALSP. Effective scales
for measurement of cognitive decline should be fully validated,
have inter-relater reliability, show sensitivity to early cognitive
changes as well capture decline during progression of the disease
and be acceptable to both the patient and assessor (99). Reports of
the performance of patients with ALSP on specific cognitive tests
have been limited to case reports (63). Given these limitations
and the known localization of pathology in patients with ALSP,
cognitive tests probing frontal lobe functions, both cortical
and subcortical, including attention, processing speed, working
memory and cognitive flexibility, are of particular interest.
The Montreal Cognitive Assessment (MoCA) is a validated
tool for rapid screening of mild cognitive impairment (100, 101).
The MoCA is extensively used as a clinical trial endpoint and for
clinical screening in practices to measure cognitive dysfunction
in patients with PD or dementia because of its high sensitivity
(100%) and specificity (87%) (102, 103).
Other commonly used assessment scales for cognitive decline
are the Mini-Mental State Examination (MMSE) (104) and MiniCog Test (105). The MMSE has acceptable test-retest and interrelater reliability, with a sensitivity of 69-91% and a specificity
of 87-99% (103). The MMSE has advantages over other scales
because of its ability to quantitate cognitive dysfunction over
time and to definitively assess treatment effects in clinical trials.
A disadvantage of MMSE is its lack of sensibility to mild
cognitive disruptions, particularly those related to frontal lobe
dysfunction (106).
Several other cognitive tests may be appropriate for ALSP
clinical trials. The Trail Making Test (TMT) measures cognition
related to processing speed, sequencing, mental flexibility and
visual/motor skills (107). The Wisconsin Card Sorting Test
(WCST) is aimed at higher level cognitive processes, such
as attention, perseverance, abstract thinking and adaption to
change (108). The WCST employs two card packs with four
stimulus cards and 64 response cards in each pack. The Symbol
Digit Modalities Test (SDMT) examines divided attention, visual
scanning, tracking, processing speed and motor speed (109).
A smartphone-based symbol-digit SDMT has recently been
developed to reduce the time of the test (110). The Verbal Fluency
Test is primarily designed to measure executive dysfunction
(111). The Stroop Color and Word Test (SCWT) assesses the
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Motor and Sensory Dysfunctions
Scales that are specifically designed to score motor and sensory
dysfunctions of ALSP are not currently available. As the early
and progressive stages of ALSP display some motor and nonmotor symptoms that are comparable to PD (14), scales used in
PD clinical trials may serve as predictive clinical endpoints for
interventional clinical trials of ALSP.
Based upon the four components of the Movement Disorder
Society (MDS)-sponsored revision (120) of the Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS), this validated
scoring system may be applicable to ALSP. The MDS-UPDRS
items are rated by clinicians, patients or both. There are four
main components each of which includes several questions
related to sensory and motor disabilities. With the exclusion of
part 4 which quantifies complications of dopamine replacement
therapies, the MDS-UPDRS is a comprehensive scoring tool
for motor and sensory complications and quality of life and,
therefore, may serve as a clinically meaningful and predictive
endpoint to assess therapies in interventional clinical trials of
ALSP. However, the overlapping pyramidal and extrapyramidal
symptoms in ALSP may introduce scoring limitations and
should be considered during the endpoint selection process.
The EDSS is a frequently used disability scale for clinical
trials in MS with high relevance to symptoms and functions
of patients with ALSP (121). Due to some similarity in the
symptoms of ALSP and MS, the EDSS may be another tool to
quantify disability endpoints over time in clinical trials of ALSP.
The following functional systems are rated: pyramidal (muscle
weakness), cerebellar (ataxia, loss of balance, tremor), brainstem
(speech problems, swallowing, nystagmus), sensory (numbness,
loss of sensation), bowel and bladder (incontinence), visual and
cerebral (thinking, memory, fatigue), walking distance and usage
of walking aid and/or extension wheelchair.
Several tools that directly measure how a patient functions
(gait, strength, spasticity) or feels may provide clinically
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acceptable internal consistency and excellent reliability and
validity in patients with dementia (142).
Finally, given the heterogeneity of potential symptom
presentations and combinations in ALSP, particularly in the
early symptomatic stages, patient-specific and patient-centered
outcome measures may also be valuable approaches (143).

meaningful endpoints for clinical trials in ALSP. Measurement
of the distance walked within a specific time period is evaluated
by the 2- or 6-min walk test (122). The Timed Up and
Go (TUG) test identifies mobility and balance abnormalities.
(123). The Spastic Paraplegia Rating Scale (SPRS) is a reliable
and validated measurement of the severity and progression of
spasticity (124). Limb and muscle spasticity can also be scored
by the Modified Ashworth Scale (MAS), a scale that is widely
used in clinical practice for rating the spasticity of extremities and
in clinical trials for an assessment of the therapeutic efficacy of
spasticity (125).

Magnetic Resonance Imaging and Other
Biomarker Surrogates
Analysis of MRI scans has demonstrated that white matter
damage is a congruous finding in most patients with ALSP. White
matter abnormalities occur early and are progressive. Given the
rapid confluence of patchy or focal T2-weighted hyperintensities
and progression of cortical atrophy during the course of ALSP,
longitudinal MRI scans on a yearly follow-up basis after diagnosis
of ALSP have been recommended to generate a more accurate
prognosis of the disorder (14) and may serve as reliable surrogate
endpoints for clinical trials.
The MRI severity scoring system, which was developed based
on MRI scans of 15 patients with ALSP, may serve as an
endpoint for interventional trials of ALSP. The semi-quantitative
severity scoring of white matter lesions and brain atrophy is
based on a range of 0 (minimal severity) to 57 (maximum
severity). Analysis of MRI scans from these 15 patients showed
that 14 of the patients (93%) had white matter lesions and
the mean total severity score was 16.6 points (range, 10-33.5
points). Although this MRI scoring system shows promise, it
requires further validation by prospective longitudinal studies of
additional patients and a standard imaging protocol (50, 53).
A widely used scoring method for MRIs of leukodystrophies,
the Loes severity score, may also serve as a surrogate clinical
endpoint for ALSP clinical trials. This scoring method employs
a severity score of 0-34 points for white matter lesions and, with
minor modifications, has the capability to detect progression,
stabilization and improvement of multiple leukodystrophies
(144). Definitive longitudinal MRI studies of progression of white
matter abnormalities have not been conducted in patients with
ALSP. In one case study of a family in which seven members
were diagnosed with HDLS, sequential images in the proband
(one MRI at the onset of the disorder and two MRIs during
the follow-up period) displayed a progressive, confluent frontal
predominant HDLS with symmetrical cortical atrophy (49).
Longitudinal MRI alterations were also detected in seven
patients with HDLS through the MRI rating scale. Total MRI
scores varied from 12 to 44, white matter lesion scores ranged
from 11 to 32 and atrophy scores ranged from 1 to 12. The
severity of MRI scores increased significantly with the duration
of HDLS (total score, p < 0.01, white matter lesion score, p <
0.01 and atrophy score, p < 0.01). The mean changes in scores on
a year basis were 3.7 ± 1.5 for the total score, 2.5 ± 1.1 for white
matter lesion score and 1.3 ± 0.5 for the atrophy score (52).
Rapid Estimation of Myelin for Diagnostic Imaging provides
a validated and robust myelin quantification that detects diffuse
demyelination in normal-appearing tissue in MS (145). This
demyelination is associated with both cognitive and clinical
disability. Because the technique is rapid with automatic

Impaired Activities of Daily Living and
Physical and Behavioral Dysfunction
Several scales rate the patient’s feelings about how daily activities
of life are affected by their health disorder. These additional
scales may serve as congruent, clinically predictive endpoints of
efficacy in clinical trials of therapeutic agents for ALSP. The Goal
Attainment Scale (GAS) is a clinician- and patient-scored tool
that rates three health goals that are developed by the patient.
The patient’s progress toward goal achievement is evaluated on
a five-point scale from −2 (unfavorable) to +2 (best anticipated
outcome) (126). The visual analog scale (VAS) (127), Clinical
Global Impressions of Severity (CGI-S) and Improvement (CGII) (128), 36-item Short Form Health Survey (SF-36) (129)
and Schwab and England Activities of Daily Living (ADL)
for PD (130) (described in Supplementary Table 4) are widely
accepted global scoring systems for MS and PD and, therefore,
may be beneficial for patient and clinician assessment of the
dysfunctional effects of ALSP on activities of daily life. Disability
and functional scales (described in Supplementary Table 4),
such as the Total Functional Capacity (TFC) for Huntington’s
Disease (131), the Karnofsky Performance Status (KPS) (132) and
the Cortical Basal ganglia Functional Scale (CBFS) (133) may also
prove to yield clinically meaningful endpoints for ALSP clinical
trials. The EuroQOL 5 dimensions questionnaire (EQ-SD) scale
is used for MS patients and may be applicable to ALSP (134).
Scales that measure behavioral impairment of patients
are likely to generate clinically meaningful data in clinical
trials of ALSP (Supplementary Table 5). These widely used
neuropsychiatric tools evaluate depression with the Hamilton
Rating Scale for Depression (HAM-D) (135, 136) and the
Beck Depression Inventory (BDI) (137, 138) and psychosis
using the Neuropsychiatric Interview (NPI) (139). Hospital,
anxiety, depression scale (HADS) is a useful self-assessment
scale for anxiety and depression and a screening tool for mood
disorders (140).
Given the severity and devastating progression of ALSP,
it will be meaningful to evaluate the behavioral burden
that affects the daily lives of caregivers. The Zarit Burden
Interview (ZBI) is a commonly used measure of caregiver
burden (141). This scoring system covers a wide range of
dimensions that include consequences of caregiving, patient
dependence, exhaustion and uncertainty, guilt or self-criticism,
embarrassment, anger or frustration, psychological burden,
emotional reactions and personal/role strain. ZBI has shown
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postprocessing and U.S. FDA approval, it may be a clinically
feasible biomarker suitable for monitoring myelin dynamics and
evaluation of treatments aimed at remyelination of ALSP.
Biochemical assays of levels of various soluble biomarkers
in CSF (tau proteins, NfL proteins and glial fibrillary acidic
protein) and in plasma (NfL) of ALSP patients may serve as
meaningful surrogate endpoints for clinical trials (14, 20, 24,
40, 67, 86). These biomarkers are etiologic factors that underlie
neural, axonal and glial cell damage, and may be considered
as trial endpoints in conjunction with MRI analysis. Further
development and validation of such assays are important for early
translational trials in ALSP.

posture, balance, gait, dexterity, voice and speech patterns, facial
expression, eye tracking, medication).
Development of precision medicine subtypes for common
diseases, such as PD and AD, and deep phenotype maps based on
digital sensing technologies of rare disease populations, such as
ALSP, could capture therapeutic responsiveness to experimental
treatment paradigms (151–156).

Digital Biomarkers

Progressive neurologic disorders invoke a heavy burden on
afflicted patients, caregivers and society (157). Although data on
the patient and caregiver burden of ALSP are unavailable, data
from other progressive neurological disorders provide insight
into the potential burden of ALSP on patients and caregivers.
Research questionnaires have been used to understand the
unmet medical needs of progressive neurologic disorders by
directly seeking input from the afflicted patients. A crosssectional study of 1,205 patients with MS was conducted
using a questionnaire to collect information on demographics
(sex, age, education, employment), clinical status (form, disease
duration, disability level) and unmet healthcare and social
needs (12 items scored as yes/no) (158). Psychological support
(27.5%) was the greatest unmet healthcare need, followed by
temporary admission to rehabilitation (9.8%), access to technical
aid (6.7%), access to drugs (5.4%) and lack of nursing home
admission (3.2%). Social care needs included assistance with
transportation (41%), financial support, architectural barriers,
personal assistance (>30%), career guidance and adaptation
to workplace (>10%). Unmet healthcare needs were linked to
clinical factors, such as disease progression and level of disability.
Because there is a paucity of data underlying the major
burden of the physical, psychological, emotional and financial
impositions of ALSP on patients, families and caregivers, it is
appropriate to examine the burden of closely related neurologic
disorders, such as ALS and FTD. ALS and FTD are both
characterized as rare diseases by Genetic and Rare Diseases
(GARD), National Organization for Rare Disease (NORD) and
Orphanet. These are meaningful comparative disorders for
ALSP because both are rare diseases that affect motor function,
cognition and mental health and have unmet medical needs.
The burden of devastating symptoms of ALS disrupts quality
of life and shortens the lifespan of patients. The financial burden
to patients, families and payers is substantial. A case study of
the costs of care for individual patients was conducted in the
United States over a 10-year period (2001-2010) (159). Total
costs for the duration of ALS were $1,433,992 (85% paid by
insurance, 9% paid by patient and family and 6% paid by charity).
The greatest costs involved in-home caregivers ($669,150),
ventilation ($212,430) and hospital care ($114,558). These cost
factors are particularly burdensome for patients because they
markedly influence treatment decisions. It is important to note
that this case study did not address the indirect financial

PATIENT AND CAREGIVER PERSPECTIVE
OF BURDEN DUE TO UNMET MEDICAL
NEED

Traditional methods of assessing neuromotor disorders, such
as clinical rating scales, are subjective and prone to human
bias. During the last decade, a multitude of technologybased objective measures of human behavior and function
have been developed, bringing with them the promise of
substantial change to the diagnostic, monitoring and therapeutic
landscape in neurodegenerative diseases (146, 147). Sensors,
mobile communications, cloud computing, advanced analytics
and the Internet of Things (wireless connectivity of all electronic
devices) are among the innovations that have the potential to
transform healthcare and the approach to patients with chronic,
complex and fluctuating disorders (148). These devices offer
potential novel approaches to more accurately assess motor
dysfunction in interventional clinical trials of ALSP.
Wearable activity trackers are electronic monitoring devices
that enable users to track and monitor their health-related
physical fitness metrics, including the number of steps taken,
level of activity, walking distance, heart rate and sleep patterns.
Despite the proliferation of these devices in various contexts of
use and rising research interest, there is limited understanding of
the broad research landscape (149).
Although commercial grade activity monitors like Fitbits and
the Apple Watch provide objective data, the results are limited to
activity tracking only. Medical-grade wearable precision motion
sensor solutions overcome these limitations. Such platforms
can deliver objective, high-frequency data combined with
scientifically validated endpoints that are specific to a patient
population (148).
The use of consumer wearable technologies in medicine
is becoming increasingly more common. For instance, in
the field of sleep medicine, the use of actigraphy for sleep
monitoring may be used to supplant more traditional methods
like polysomnography due to its validity, lower cost and
ability to evaluate individuals in their homes over a longer
period of time (150). Advanced wearable technologies can also
precisely monitor skin conductance, respiratory rate, blood
pressure and oximetry and provide surface electromyography
(EMG), electrocardiography (ECG) and electroencephalograpy
(EEG) tracings. Furthermore, the ability to collect multiple
aspects of human function with smart devices (mobile phones,
tablets and smart watches) provides additional opportunities to
collect and analyze numerous clinically relevant parameters (e.g.,
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TABLE 1 | Gaps in ALSP specific published literature of clinical manifestations.
Clinical manifestations of ALSP

ALSP-specific literature
references

Total ALSP-specific
literature references

Genetics

(6, 9, 13, 14, 17–42)

(30)

Neuropathology

(6, 14, 17, 28, 29, 32, 43–48)

(12)

Imaging

(1, 6, 13, 22, 47, 49–59)

(16)

Prevalence

(5, 6, 9, 13, 14, 58, 60, 61)

(8)

Clinical course

(6, 13, 14, 53, 62, 63)

(6)

Diagnosis and clinical evaluation

(13, 14, 30, 31, 53, 64–67)

(9)

Current treatment for management of symptoms

(6, 14, 27, 44, 48, 68–72)

(10)

Potential neuropathophysiologic biomarkers

(28, 33, 62, 67)

(4)

Current and proposed interventional clinical studies of therapeutics

(27, 29, 48, 58, 70, 71, 91, 94)

(8)

Cognitive decline endpoint

(6, 14, 63)

(3)

Motor and sensory dysfunction endpoints

(14)

(1)

Impaired activities of daily living and physical and behavioral dysfunction
endpoints

None

None

Magnetic resonance imaging and other biomarker surrogate endpoints

(14, 20, 24, 49, 50, 52, 53, 67)

(8)

Digital biomarker endpoints

None

None

Patient and caregiver perspective of burden due to unmet medical need

None

None

of ALSP will require a patient-focused, precision medicine
therapeutic approach by the multidisciplinary caregiver team
and foundation and support groups to address the cause of
the disorder, management of motor and sensory symptoms and
careful attention to quality of life issues.

detriments to patients, such as lost wages, productivity and
terminated employment.
The burden of the progressive symptoms of FTD and the
economic burden are staggering for patients, families and
caregivers. A robust 250-item survey was administered to
primary caregivers of patients with FTD to estimate the cost
burden of the disorder (160). The survey was completed by
674 of the 956 caregivers. Direct and indirect annual costs of
FTD were $47,916 and $71,737, respectively, and resulted in
an annual per-patient charge of $119,653. Elderly patients with
later stages of behavioral-variant FTD had higher direct costs
whereas male patients aged < 65 years had higher indirect costs.
The impact of FTD on the patient and family resulted in a
mean reduction in household income ranging from $75,000 to
$99,000 (12 months before diagnosis) to $50,000 to $59,000 (12
months after diagnosis). This dramatic loss of household income
was related to lost days of employment and to early departure
from employment. The profound economic burden of FTD may
be reduced in the future through accurate and early diagnosis,
effective treatments to target cause of the disorder and improved
professional services.
The financial burden of MS has been explored in cohort
studies conducted with patient data extracted from the Swedish
Multiple Sclerosis Register (SMSreg). These MS studies have
shown that the level of cognitive function correlates directly with
the amount of work disability (161) and quantity of income
independent of physical disability (162). Patients with relapsing,
remitting MS also earned twice the income of patients with
progressive MS (163).
ALSP is a rare, progressive, debilitating disorder and its
treatment is an unmet medical need. The signs and symptoms
of ALSP present a major burden for daily living, cost of
care and life expectancy of afflicted patients. The treatment
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GAP ANALYSIS OF CLINICAL
MANIFESTATIONS
There is a paucity of published clinical research literature for
ALSP, a rare neurodegenerative disorder. The limited number of
published clinical research studies is comprised primarily of case
reports with small numbers of patients and absence of controls.
Therefore, formal gap analysis of ALSP clinical manifestations
was not conducted for this comprehensive review. In an effort
to gain some understanding of the gaps in clinical manifestations
of ALSP, a count of ALSP-specific publications was conducted.
Table 1 lists the references and total number of references
for publications that are ALSP-specific for each of the clinical
manifestations. The most conspicuous gaps in the literature were
identified as the potential efficacy endpoints for future clinical
trials. Endpoints such as cognitive decline, motor and sensory
dysfunction, impaired activities of daily living with physical
and behavioral dysfunction, digital biomarkers and patient and
caregiver perspective of burden due to unmet medical need had
the fewest (0-3) ALSP-specific literature references. These gaps
are likely related to the low global incidence of ALSP patients
which have restricted the number of adequate and controlled
clinical trials. Future clinical studies of ALSP should target the
development of clinically meaningful, congruent, specific and
validated efficacy endpoints that will accelerate the discovery of
safe and effective therapies for this rare disorder.
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LIMITATIONS

and interventional clinical studies of ALSP, the information
gained from this review can serve as a foundation for the
strategy and design of future clinical trials, with clinically
meaningful and congruent efficacy endpoints for patients with
ALSP. These clinical trials will be designed to elicit determinative
assessments for the development of therapeutics for ALSP, an
orphan neurodegenerative disease with an unmet medical need,
target with precision the etiology and alleviate symptoms in an
effort to reverse, halt or slow progression of ALSP.

There were limitations to this comprehensive review of the
clinical manifestations of ALSP. Most of the clinical data were
derived from limited numbers of patients in published case
studies. Due to the paucity of ALSP-specific clinical literature,
some gaps were evident in the clinical manifestations of
the disorder, particularly efficacy endpoints. Lack of patient
medical records associated with the case studies may have
resulted in inaccurate, incomplete or missing assessments of
symptoms and disease progression. Quality control of case
studies was restricted to inclusion and exclusion criteria with no
additional quality parameters. There was considerable variation
in geographic location of the clinics involved in the case studies
and this may have created inconsistent interpretation of the
clinical manifestations.
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